Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy -
Glickman Urological & Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH, USA -
Minerva Endocrinol (Torino). 2024 Mar;49(1):13-24. doi: 10.23736/S2724-6507.23.04080-0. Epub 2024 Jan 19.
This single-center real-life study was conducted to evaluate the most effective combination of nutraceuticals and the most appropriate indications for the treatment of male infertile patients.
Infertile patients aged 20-55 years were treated with a combination of antioxidants (Androlen; Enfarma, Misterbianco, Catania, Italy) (group A), with Androlen (Enfarma) and a mixture of fibrinolytic molecules (Lenidase, Enfarma) (group B), or Androlen (Enfarma) and other molecules different from those used for the patients of the group B (group C). Patients were also subdivided according to the presence of varicocele, mild testicular hypotrophy, idiopathic infertility, and chronic male accessory gland infection.
Forty-three patients were enrolled. In the overall analysis, only progressive motility significantly improved after therapy. Subgroup analysis showed a significant increase in progressive motility, total motile sperm count (TMSC), and in the percentage of alive spermatozoa after treatment in the group A. Progressive motility improved significantly in patients with varicocele, while the TMSC in patients with varicocele and those with idiopathic infertility. The percentage of alive spermatozoa increased in patients with testicular hypotrophy.
Treatment with antioxidants increased progressive sperm motility, especially in patients with varicocele or idiopathic infertility.
本单中心真实世界研究旨在评估营养补充剂的最佳组合以及治疗男性不育患者的最佳适应证。
将年龄在 20-55 岁的不育患者采用抗氧化剂（Androlen；Enfarma，Misterbianco，Catania，意大利）（A 组）、Androlen（Enfarma）和纤维蛋白溶解分子混合物（Lenidase，Enfarma）（B 组）或 Androlen（Enfarma）和不同于 B 组患者所用的其他分子（C 组）联合治疗。根据精索静脉曲张、轻度睾丸萎缩、特发性不育和慢性男性附属性腺感染的存在情况，患者还进行了亚组分析。
共纳入 43 例患者。在总体分析中，只有治疗后精子的前向运动能力显著改善。亚组分析显示，A 组的前向运动精子比例、总活力精子数（TMSC）和活精子比例在治疗后均显著增加。精索静脉曲张患者的前向运动精子比例显著改善，精索静脉曲张和特发性不育患者的 TMSC 显著增加，睾丸萎缩患者的活精子比例增加。
抗氧化剂治疗可提高精子的前向运动能力，尤其是精索静脉曲张或特发性不育患者。
